Welcome to our dedicated page for 10X Genomics news (Ticker: TXG), a resource for investors and traders seeking the latest updates and insights on 10X Genomics stock.
10X Genomics, Inc. (TXG) drives innovation in life sciences through advanced single cell and spatial biology solutions. This news hub provides investors and researchers with essential updates about technological advancements, strategic partnerships, and financial developments shaping the future of biological research.
Access authoritative information on product launches, peer-reviewed study validations, and regulatory milestones. Our curated collection includes earnings reports, executive commentary, and analyses of how TXG's platforms enable breakthroughs in oncology, immunology, and neuroscience research.
Key updates cover instrument innovations, software enhancements, and collaborations with leading research organizations. Monitor progress in making high-resolution cellular analysis more accessible to academic institutions and biopharmaceutical developers worldwide.
Bookmark this page for streamlined access to verified TXG developments. Check regularly for insights into how the company continues redefining biological discovery through integrated hardware, consumables, and data analysis solutions.
10x Genomics, Inc. (TXG) reported Q2 2021 revenues of $115.8 million, marking a 170% increase year-over-year and a 9% increase sequentially. This growth was driven by higher consumables revenue amid decreased pandemic impacts. The company launched Chromium X and began shipping Visium Spatial Gene Expression for FFPE. Gross margin improved to 96% due to a reversal of $14.7 million in accrued royalties linked to a settlement with Bio-Rad. While operating expenses rose to $121.3 million, the operating loss decreased to $10.3 million. Full-year revenue guidance of $480 million to $500 million remains unchanged.
10x Genomics, Inc. (Nasdaq: TXG) announced a global settlement and cross-license agreement with Bio-Rad Laboratories, resolving all ongoing litigation. The agreement provides both companies a non-exclusive, royalty-bearing license for single cell analysis products, excluding spatial and digital PCR products. 10x Genomics has invested nearly $1 billion in R&D, resulting in over 1,100 patents, underscoring the strength of its innovation. The settlement eliminates legal disputes, allowing both companies to focus on product development and market growth.
10x Genomics announces the launch of its new Chromium X Series, a state-of-the-art platform for single cell analysis that enables routine experiments involving millions of cells at just two cents per cell. This innovative series includes the Chromium X and Chromium iX, facilitating seamless upgrades for expanding research projects. The Chromium X is designed to support various applications, including drug screening and biomarker identification. Available for pre-order, it is expected to ship later this quarter.
10x Genomics (Nasdaq: TXG) will report its Q2 2021 financial results on August 4, 2021, after market close. A conference call will follow at 1:30 p.m. PT to discuss the results and company outlook. The event will be accessible via live webcast, archived for 45 days. 10x Genomics focuses on technologies for biological analysis, with a portfolio of over 1,100 patents and products used by top global research institutions and pharmaceutical companies. The company emphasizes its commitment to advancing human health through innovative solutions.
10x Genomics announced the launch of Visium Spatial Gene Expression for FFPE, a groundbreaking assay that allows researchers to conduct unbiased whole transcriptome analysis on preserved tissue samples. This innovation addresses the challenges presented by FFPE processing, which often damages nucleic acids, hindering transcriptomic evaluations. Key features include full tissue coverage and high cellular resolution, making it compatible with histological techniques. Institutions such as the Keck School of Medicine are already utilizing this technology for impactful research.
10x Genomics (Nasdaq: TXG) announced its participation in two upcoming investor conferences. The William Blair 41st Annual Growth Stock Conference will feature a fireside chat on June 2, 2021, at 2:20 p.m. ET. Following this, the Goldman Sachs 42nd Annual Global Healthcare Conference will include a fireside chat on June 9, 2021, at 3:50 p.m. ET. Interested parties can access live and archived webcasts on the company's website.
10x Genomics specializes in life science technologies aimed at advancing human health, with a robust patent portfolio and significant global research adoption.
10x Genomics (TXG) reported a strong Q1 2021 with revenue of $105.8 million, up 47% year-over-year from $71.9 million in Q1 2020. The growth was driven by increased consumables revenue linked to a larger instrument installed base. Gross margin improved to 84%, up from 79% the previous year. Despite a $10.2 million operating loss, the net loss reduced to $11.6 million from $21.1 million. The company maintains full-year revenue guidance of $480 million to $500 million, indicating a potential 61% to 67% growth over 2020.
10x Genomics, Inc. (Nasdaq: TXG) has announced its participation in the BofA Securities 2021 Virtual Healthcare Conference. The management is scheduled to present on May 12, 2021, at 3:30 p.m. ET. Interested individuals can access a live and archived webcast of the presentation via the company's website under the 'Investors' section.
10x Genomics focuses on life science technology, providing integrated solutions, including instruments and software, to analyze biological systems. The company has a notable patent portfolio with over 1,000 patents and is widely adopted by leading global research institutions.
10x Genomics (Nasdaq: TXG) will release its Q1 2021 financial results on May 5, 2021, after market close. A live webcast is scheduled for 1:30 PM PT to discuss these results along with business developments and future outlook. The webcast will be accessible through the company's website and will be archived for at least 45 days. 10x Genomics focuses on providing innovative life science technology solutions that enhance biological research and has a robust patent portfolio.
10x Genomics, Inc. (TXG) announced the launch of its Chromium Single Cell Gene Expression Low Throughput (LT) Kit, aimed at making single cell analysis more accessible to researchers. This innovative kit significantly reduces the startup costs for experiments. The LT Kit is designed for experiments ranging from a few hundred cells to high-throughput studies.
Additionally, the CellPlex solution allows multiplexing of up to 96 samples on a single chip, enhancing experimental capability. Both products facilitate cost-effective research and are part of 10x Genomics' commitment to democratizing scientific discovery.
FAQ
What is the current stock price of 10X Genomics (TXG)?
What is the market cap of 10X Genomics (TXG)?
